Paul Capital in $45m Merck royalty deal

Just days after the drug was approved by federal drug authorities, San Francisco-based Paul Capital announced a partial royalty interest in ROTATEQ, a Merck vaccine.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this